Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
出版年份 2020 全文链接
标题
Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
作者
关键词
-
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-02-17
DOI
10.1007/s10549-020-05564-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
- (2017) Lesley-Ann Martin et al. Nature Communications
- Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
- (2017) Tomas Reinert et al. Frontiers in Oncology
- AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
- (2016) H. M. Weir et al. CANCER RESEARCH
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
- (2016) A Harrod et al. ONCOGENE
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
- (2015) P. Wang et al. CLINICAL CANCER RESEARCH
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
- (2014) Y. Wang et al. CANCER RESEARCH
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor
- (2013) Hisham Mohammed et al. Cell Reports
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
- (2012) Matthew J. Sikora et al. BREAST CANCER RESEARCH AND TREATMENT
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
- (2008) Matthew J. Sikora et al. BREAST CANCER RESEARCH AND TREATMENT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started